Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels

Journal of Bone and Mineral Research

Volumn 19, Issue 9, 2004, Pages 1518-1524

  Uebelhart, Brigitte ^a,c   Herrmann, François ^a   Pavo, Imre ^b   Draper, Michael W ^b   Rizzoli, René ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bone; Males; Osteoporosis; Selective estrogen receptor modulators; Sex hormones

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CREATININE; DEOXYPYRIDINOLINE; ESTRADIOL; OSTEOCALCIN; PLACEBO; RALOXIFENE; SEX HORMONE; TESTOSTERONE; AMINO ACID; BIOLOGICAL MARKER; CREATINE;

ADULT; AGED; ARTICLE; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; HORMONAL THERAPY; HORMONE DETERMINATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TESTOSTERONE BLOOD LEVEL; URINALYSIS; BLOOD; DRUG EFFECT; HEALTH; MIDDLE AGED; URINE;

AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE REMODELING; CREATINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; HEALTH; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RALOXIFENE; TESTOSTERONE;

EID: 16644396733     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040503     Document Type: Article

References (27)

1. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
2. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617.
3. Gluck O, Maricic M 2002 Raloxifene: Recent information on skeletal and non-skeletal effects. Curr Opin Rheumatol 14:429-432.
4. Doran PM, Riggs BL, Atkinson EJ, Khosla S 2001 Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16:2118-2125.
5. Khosla S, Melton LJ III, Riggs BL 2002 Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443-1450.
6. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061.
7. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698.
8. Bilezikian JP, Morishima A, Bell J, Grumbach MM 1998 Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603.
9. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER 1997 Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91-95.
10. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC 1997 Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755-1759.
11. Greendale GA, Edelstein S, Barrett-Connor E 1997 Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bemardo Study. J Bone Miner Res 12:1833-1843.
12. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274.
13. Center JR, Nguyen TV, Sambrook PN, Eisman JA 1999 Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 84:3626-3635.
14. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW 2000 Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85:3276-3282.
15. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, Duboeuf F, Delmas PD 2001 Bioavailable estradiol may be an important determinant of osteoporosis in men: The MINOS study. J Clin Endocrinol Metab 86:192-199.
16. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM 2001 Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555-3561.
17. Barrett-Connor E, Mueller JE, von Muhlen DG, Laughlin GA, Schneider DL, Sartoris DJ 2000 Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 85:219-223.
18. Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG 2001 The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 86:2869-2874.
19. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560.
20. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672.
21. Perneger TV 1998 What's wrong with Bonferroni adjustments. BMJ 316:1236-1238.
22. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C 1996 A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835-842.
23. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO III 2000 Hormonal, lipoprotein, and vascular effects of the selective estrogen receptor modulator raloxifene in hypercholesterolemic men. Am J Cardiol 85:1491-1494.
24. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL 1995 Antiestrogenic properties of raloxifene. Pharmacology 50:209-217.
25. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB 1998 Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 83:6-13.
26. Reindollar R, Koltun W, Parsons A, Rosen A, Siddhanti S, Plouffe L Jr 2002 Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil Steril 78:469-472.
27. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA 2002 Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220.